Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Roberta Gagliardini; Barbara Rossetti; Claudia Bianco; S Rusconi; Manuela Colafigli; R Prinapori; D Francisci; A Fantauzzi; G Orofino; F Vignale; Simona Di Giambenedetto; Andrea De Luca

doi:10.7448/IAS.17.4.19818

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Roberta Gagliardini, Barbara Rossetti, Claudia Bianco, S Rusconi, Manuela Colafigli, R Prinapori, D Francisci, A Fantauzzi, G Orofino, F Vignale, Simona Di Giambenedetto, Andrea De Luca

Research output: Contribution to journal › Conference article › peer-review

Abstract

HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.

Original language	English
Pages (from-to)	19818-19818
Number of pages	1
Journal	Journal of the International AIDS Society
Volume	17
DOIs	https://doi.org/10.7448/IAS.17.4.19818
Publication status	Published - 2014
Event	HIV Drug Therapy Glasgow Congress 2014 - Glasgow Duration: 2 Nov 2014 → 6 Nov 2014

Keywords

HCV
HIV
Risk factor
liver
therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7448/IAS.17.4.19818

Cite this

Gagliardini, R., Rossetti, B., Bianco, C., Rusconi, S., Colafigli, M., Prinapori, R., Francisci, D., Fantauzzi, A., Orofino, G., Vignale, F., Di Giambenedetto, S., & De Luca, A. (2014). Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study. Journal of the International AIDS Society, 17, 19818-19818. https://doi.org/10.7448/IAS.17.4.19818

@article{97296dd9ed9f487a82b049fcade4a3e6,

title = "Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study",

abstract = "HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.",

keywords = "HCV, HIV, Risk factor, liver, therapy, HCV, HIV, Risk factor, liver, therapy",

author = "Roberta Gagliardini and Barbara Rossetti and Claudia Bianco and S Rusconi and Manuela Colafigli and R Prinapori and D Francisci and A Fantauzzi and G Orofino and F Vignale and {Di Giambenedetto}, Simona and {De Luca}, Andrea",

year = "2014",

doi = "10.7448/IAS.17.4.19818",

language = "English",

volume = "17",

pages = "19818--19818",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "London: BioMed Central",

note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 02-11-2014 Through 06-11-2014",

}

Gagliardini, R, Rossetti, B, Bianco, C, Rusconi, S, Colafigli, M, Prinapori, R, Francisci, D, Fantauzzi, A, Orofino, G, Vignale, F, Di Giambenedetto, S & De Luca, A 2014, 'Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study', Journal of the International AIDS Society, vol. 17, pp. 19818-19818. https://doi.org/10.7448/IAS.17.4.19818

TY - JOUR

T1 - Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

AU - Gagliardini, Roberta

AU - Rossetti, Barbara

AU - Bianco, Claudia

AU - Rusconi, S

AU - Colafigli, Manuela

AU - Prinapori, R

AU - Francisci, D

AU - Fantauzzi, A

AU - Orofino, G

AU - Vignale, F

AU - Di Giambenedetto, Simona

AU - De Luca, Andrea

PY - 2014

Y1 - 2014

N2 - HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.

AB - HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.

KW - HCV

KW - HIV

KW - Risk factor

KW - liver

KW - therapy

KW - HCV

KW - HIV

KW - Risk factor

KW - liver

KW - therapy

UR - http://hdl.handle.net/10807/61288

U2 - 10.7448/IAS.17.4.19818

DO - 10.7448/IAS.17.4.19818

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19818

EP - 19818

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow Congress 2014

Y2 - 2 November 2014 through 6 November 2014

ER -

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this